Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response

Psychoneuroendocrinology. 2007 May;32(4):411-6. doi: 10.1016/j.psyneuen.2007.01.006. Epub 2007 Mar 6.

Abstract

Serotonin (5-HT) 5-HT1A receptor seems to play an important role in the pathophysiology of major depression and in the mechanism of action of antidepressants. In vivo function of 5-HT1A receptors can be monitored using specific pharmacological challenge tests. The present study aimed at exploring the adaptative 5-HT1A receptor changes in depressed patients before and after 8 week treatment with citalopram. The study population consisted of 30 consecutive outpatients of both sexes aged 18-45 years with major depressive disorders (DSM-IV). Basal score in the Hamilton Rating Scale for Depression (HRSD) was higher than 17. Therapeutic response was defined as a 50% decrease in the HRSD score. The hypothermic and endocrine responses (ACTH, cortisol, and prolactin) induced by the 5-HT1A receptor agonist, buspirone (30 mg p.o.) were measured. After 8 weeks on citalopram, the delta max of hypothermic response elicited by buspirone was markedly decreased (p<0.001). Patients showed a decrease in responses to ACTH (delta max p=0.005; AUC p=0.028) and cortisol (delta max p=0.05). However, the prolactin response increased (delta max p=0.02; AUC p=0.005). There was a significant correlation between the therapeutic effect and reductions of ACTH (r=0.883; p<0.001) and cortisol (r=0.610; p=0.001) responses. Changes induced by citalopram support an alteration of 5-HT1A receptors in major depression. A decrease in the overactivity of the HPA axis may be one factor associated with the response to citalopram.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenocorticotropic Hormone / blood
  • Adult
  • Anti-Anxiety Agents / administration & dosage
  • Anti-Anxiety Agents / adverse effects
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Buspirone / administration & dosage
  • Buspirone / adverse effects
  • Buspirone / therapeutic use*
  • Citalopram / pharmacology*
  • Citalopram / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / metabolism
  • Female
  • Humans
  • Hydrocortisone / blood
  • Hypothermia / chemically induced*
  • Male
  • Middle Aged
  • Prolactin / blood
  • Receptor, Serotonin, 5-HT1A / metabolism
  • Serotonin 5-HT1 Receptor Agonists*
  • Treatment Outcome

Substances

  • Anti-Anxiety Agents
  • Antidepressive Agents, Second-Generation
  • Serotonin 5-HT1 Receptor Agonists
  • Citalopram
  • Receptor, Serotonin, 5-HT1A
  • Adrenocorticotropic Hormone
  • Prolactin
  • Buspirone
  • Hydrocortisone